Envoy Medical, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Envoy Medical filed exhibits to its Form 10-Q dated August 10, 2026, including: (1) the form of RSU Award Grant Notice and Award Agreement under the Amended and Restated 2023 Equity Incentive Plan, setting terms for restricted stock unit grants with vesting schedules and tax withholding provisions; and (2) Sarbanes-Oxley certifications signed by CEO Brent T. Lucas and Interim CFO Robert Potashnick confirming the accuracy of the quarterly report and internal controls. No specific grant amounts, participant counts, or vesting schedules are disclosed in these template documents—the bracketed fields [ ] remain blank. Robert Potashnick is identified as Interim CFO, suggesting a recent leadership change.
Why this rating
Routine filing of boilerplate equity plan documents and officer certifications. No quantified equity grants disclosed. CFO interim status noted but not elaborated. Standard periodic disclosure.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.